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Abstract
Mutations in ATRX, a chromatin remodeling protein, are associated with the
telomerase-independent ALT pathway of telomere maintenance in several types
of cancer, including human gliomas. In telomerase-positive glioma cells, we
found that by immunofluorescence ATRX localized not far from the chromosome
ends but not exactly at the telomere termini. Chromatin immunoprecipitation
(ChIP) experiments confirmed a subtelomeric localization for ATRX. Yet, shRNA-
mediated genetic inactivation of ATRX failed to trigger the ALT pathway. Cohesin
has been recently shown to be part of telomeric chromatin. Here, using ChIP, we
showed that genetic inactivation of ATRX provoked a diminution in the amount of
cohesin in subtelomeric regions of telomerase-positive glioma cells. Inactivation
of ATRX also led to a diminution in the amount of TERRAs, non coding RNAs
resulting from transcription of telomeric DNA, as well as to a decrease in RNAPII
levels at the telomeres. Our data suggest that ATRX might esta...
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Mutations in ATRX (alpha thalassemia/mental retardation syndrome X-linked), a chromatin-remodeling protein, are associated
with the telomerase-independent ALT (alternative lengthening of telomeres) pathway of telomere maintenance in several types
of cancer, including human gliomas. In telomerase-positive glioma cells, we found by immunofluorescence that ATRX localized
not far from the chromosome ends but not exactly at the telomere termini. Chromatin immunoprecipitation (ChIP) experi-
ments confirmed a subtelomeric localization for ATRX, yet short hairpin RNA (shRNA)-mediated genetic inactivation of ATRX
failed to trigger the ALT pathway. Cohesin has been recently shown to be part of telomeric chromatin. Here, using ChIP, we
showed that genetic inactivation of ATRX provoked diminution in the amount of cohesin in subtelomeric regions of telomerase-
positive glioma cells. Inactivation of ATRX also led to diminution in the amount of TERRAs, noncoding RNAs resulting from
transcription of telomeric DNA, as well as to a decrease in RNA polymerase II (RNAP II) levels at the telomeres. Our data suggest
that ATRXmight establish functional interactions with cohesin on telomeric chromatin in order to control TERRA levels and
that one or the other or both of these events might be relevant to the triggering of the ALT pathway in cancer cells that exhibit
genetic inactivation of ATRX.
The linear chromosomes of eukaryotic organisms require par-ticular protection at their extremities. Telomeres, which rep-
resent the ends of these chromosomes and contain repeated TG-
rich sequences that do not code for proteins, as well as proteins of
the shelterin complex, are essential for this protection (1). Telo-
meres protect chromosome ends from DNA repair activities that
reseal chromosome internal DNA breaks occurring during DNA
damage (2). Telomere sequences naturally erodewith ongoing cell
divisions, due to intrinsic mechanisms associated with the fixed
5=-to-3= polarity of replication of theDNAof the genome. Below a
certain threshold, shortened telomeres result in DNA damage-
induced cell cycle arrest, which is the equivalent of replicative
senescence in cultured cells.
By limiting the replicative potential of cells, telomere length
acts as a biological clock, and telomere erosion serves as a barrier
against tumorigenesis in healthy tissue. Paradoxically, telomere
erosion or telomere dysfunction also induces chromosomal insta-
bility and favors the emergence of tumors (3). However, following
cancer initiation, tumor cells must overcome the telomere-con-
trolled replicative-senescence barrier, and all have an absolute ne-
cessity to maintain functional telomeres in order to sustain con-
tinuous and unlimited cell proliferation. In around 85 to 90% of
cancer types, this occurs through upregulation of telomerase, a
reverse transcriptase with a built-in RNA template specialized in
telomeric DNA replication that is naturally repressed in most so-
matic tissues (4). In the remaining 10 to 15% of cancer types, an
alternative pathway called the ALT (alternative lengthening of
telomeres) pathway, functioning either by amplifying telomere
sequences by homologous recombination or by sister chromatid
exchange, is used (5–7). Although these numbers have been ac-
cepted for many years, a recent study performed on over 6,000
tumor tissues reported that only 3.7% of the tumors were ALT
positive, using fluorescence in situ hybridization (FISH) to probe
for ALT-specific promyelocytic leukemia (PML) bodies (8). Hu-
man gliomas are among the 5 to 15% of cancer types that can
survive, owing to either telomerase or the ALT pathway (8, 9).
Recent clinical studies have highlighted the existence of a
strong correlation between the occurrence of the ALT pathway of
telomere maintenance in several types of ALT cancers and the
presence of mutations in the ATRX (alpha thalassemia/mental
retardation syndrome X-linked) gene (10, 11). ATRX is a DNA
helicase/ATPase of the SWI2/SNF2 family that binds repeated se-
quences of DNA, particularly the G-rich ones, and has been im-
plicated mainly in chromatin remodeling (12). In the present
study, we have started to analyze possible alterations in some te-
lomeric pathways in telomerase-positive human glioma cells in
culture in response to short hairpin RNA (shRNA)-mediated ge-
netic inactivation of ATRX. Among the principal results of the
present study is the finding that partial ATRX inactivation led to a
diminution in the level of transcription of telomeric DNA into the
noncoding RNAs called TERRA. This occurred concomitantly
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with a decrease in the amounts of cohesin in subtelomeric regions.
The present data provide clues to start to understand the tight
association between the occurrence of a mutation in ATRX and
that of the ALT pathway in both cultured cell lines and tumors.
MATERIALS AND METHODS
Cell lines, plasmids, cell culture, and transfection. Glioma cancer cell
lines, 8-MG-BA andHs-683, were obtained from the American Type Cul-
ture Collection and the German Collection of Microorganisms and Cell
Cultures and cultured in minimum Eagle’s medium (MEM) and in Dul-
becco’s modified Eagle’s medium (DMEM), respectively, supplemented
with 10% fetal bovine serum (FBS) (PAA) in the presence of 5% CO2 in a
90% humidified incubator. Nontumoral human embryonic kidney
(HEK-293; ATCC) cells were cultivated in DMEM plus 10% FBS. For the
establishment of stable 8-MG-BA and Hs-683 cell lines, transfection was
performed using FuGeneHD reagent (Promega) and Lipofectamine 2000
reagent (Thermo Scientific Fisher, Invitrogen), respectively. Selection for
plasmids with neomycin resistance was performed using G418 (800 g/
ml) for 15 days before isolation of the clones. The media were replaced
every 72 h. To obtainATRX shRNA clones, cells were transfected with the
shATRX1 (sense) (5=-GATCCCCGAGGAAACCTTCAATTGTATTCAA
GAGATACAATTGAAGGTTTCCTCTTTTTA-3=) and shATRX2 (sense)
(5=GATCCCCGCAGAGAAATTCCTAAAGATTCAAGAGATCTTTAG
GAATTTCTCTGCTTTTTA-3=) shRNA constructs that had been cloned
in the pSuper.retro.neo plasmid, a generous gift from the Bérubé labora-
tory (13). The corresponding siATRX1 and siATRX2 synthetic small in-
terfering RNA (siRNA) oligonucleotides, with exactly the same sequences
(13), were obtained fromDharmacon-GEHealthcare. The IF-GFP-ATRX
plasmid for ATRX overexpression was from Michael Dyer (plasmid
45444; Addgene, Cambridge, MA). Since this plasmid has been reported
to be prone to IS10 insertion in exon 8, causing insertion of a premature
stop codon, it was sequenced in that region (https://www.addgene.org/4
5444/). No mutation could be found, and we therefore assumed (having
also visualized the expressed ATRX protein by Western blotting using
anti-ATRX antibody) that ATRX was correctly expressed in these exper-
iments (data not shown). Anti-ATRXmousemonoclonal antibody raised
against amino acids 2193 to 2492 of human ATRX (Santa Cruz Biotech-
nology; sc-55584) was used for Western blot analysis. Anti-beta-actin
chicken polyclonal antibody (Abcam; ab13822) was used as a loading
control.
Q-RT-PCR and measurement of telomeric DNA transcription into
TERRA. Total RNA was isolated from cells using Nucleospin RNA II
(Macherey-Nagel). Two micrograms of RNA was reverse transcribed us-
ing the Revertaid first-strand cDNA synthesis kit from Thermo Fisher
Scientific-Fermentas, with gene-specific primers for ATRX, and using
GAPDH expression levels as an internal control. The primers used for
quantitative real-time PCR (Q-RT-PCR) were as follows: ATRX-F, 5=-T
CCTTGCACACTCATCAGAAGAATC-3=, and ATRX-R, 5=-CGTGACG
ATCCTGAAGACTTGG-3=; GAPDH-F, 5=-GAGTCAACGGATTTGGT
CGT-3=, and GAPDH-R, 5=-GACAAGCTTCCCGTTCTCAG-3= (13).
cDNAswere amplified in aBio-RadMini-Opticon instrument usingMesa
Green qPCR Mastermix Plus (Eurogentec), together with forward and
reverse primers. Data were quantified using the Bio-Rad CFX Manager
software. For PCR amplification of total TERRA, the following telomere-
specific primers were used: Tel1b, 5=-CGGTTTGTTTGGGTTTGGGTTT
GGGTTTGGGTTTGGGGT-3=, and Tel2b, 5=-GGCTTGCCTTACCCTT
ACCCTTACCCTTACCCTTACCCT-3= (14, 15). The histograms in the
figures represent the averages and standard deviations for three replicates.
Student t tests were used for statistical analysis.
ChIP. Chromatin immunoprecipitation (ChIP) was performed ac-
cording to standard protocols. Sampleswere sonicated on ice until the size
of chromatin fragments was around 500 bp, based on agarose gel electro-
phoresis. The purified DNA recovered by ChIP was denatured in 0.2 M
NaOH by heating to 100°C for 10 min and used as a template for quanti-
tative real-time PCR amplification. To measure binding at subtelomeric
loci at positions1.1 kb from the TTAGGG telomeric repeat, we used the
following primers: 10q-2/-1122 5= primer (5=-CAGAGACGAGTGGAAC
CTGAGTAAT-3=) and 10q-2/-1122 3= primer (5=-TGGGCAAGCTGGT
CCTGTAG-3=) (16). The different distinct genomic loci matching these
primer sets computationallywere 1q, 2q, 4q, 5q, 6q, 8p, 10q, 13q, 16q, 19p,
19q, 21q, 22q (Tel), and 2qfus (internal) (16). To measure binding at
subtelomeric loci immediately adjacent to the TTAGGG repeat (bp 109
and 152), we used the XYq-1/-109 5= primer (5=-CCCCTTGCCTTGGG
AGAA-3=) and the XYq-1/-109 3= primer (5=-GAAAGCAAAAGCCCCT
CTGA-3=), matching the 9p, 19p, and XYq (Tel) genomic telomeric loci,
as well as the 13q-152 5= primer (5=-GCACTTGAACCCTGCAATACAG-
3=) and the 13q-152 3= primer (5=-CCTGCGCACCGAGATTCT-3=),
matching the 1q, 2q, 4q, 5q, 6q, 10q, 13q, 16q, 21q, and 22q (Tel) genomic
telomeric loci (16). The primers for analyzing binding at the nontelomeric
locus GAPDH were GAPDH 5= primer (5=-TGGGCTACACTGAGCACC
AG-3=) and GAPDH 3= primer (5=-GGGTGTCGCTGTTGAAGTCA-3=)
(16). Student t tests were used for statistical analysis. The antibodies used
forChIPwere anti-SMC1mousemonoclonal (Bethyl Laboratories; A300-
055A) and anti-RNA polymerase II rabbit polyclonal (Abcam 8WG16;
ab817) antibodies, as well as the sc-55584 anti-ATRXmouse monoclonal
antibody from Santa Cruz Biotechnology.
Micrococcal-nuclease digestion-based analysis of chromatin con-
densation. Nuclei isolated from 107 cells were digested with 8 mU of
micrococcal nuclease (MNase) (Sigma)/gDNA at 37°C for the indicated
times, as described previously (17). For dose-response experiments, 8 to
64 mU ofMNase/g DNA was added to chromatin before digestion for 5
min at 37°C. After digestion, the DNA was purified and separated onto a
1.5% agarose gel in the presence of ethidium bromide. Before transfer
onto nylonmembranes, theDNAwas visualized underUV light for quan-
tification of bulk chromatin digestion. Hybridization was performed with
a 0.4-kb subtelomeric probe amplified from genomic DNA with the 10q-
2/-1122 5= primer (described above) and the subtelo-10q-R 3= primer
(5=-GCGCTCTGACTTTAAGTGGT-3=). To label the probe, purified
PCR product was incubated with large Klenow fragment (NEB), random
hexamers, and [-32P]dCTP (PerkinElmer). After removal of unincorpo-
rated nucleotides, the probe was denatured and added to a prehybridized
membrane in Ultrahyb solution (Ambion). Quantifications were per-
formed with Image Gauge (GE Healthcare).
Measurements of ALT-specific C-circles.The so-called C-circle assay
was used for the detection of ALT activity. This assay, in which partially
single-stranded telomeric (CCCTAA)n DNA circles (C-circles) are de-
tected following rolling-circle amplification by the Phi29 polymerase, was
performed exactly as described previously (18).
Immunofluorescence-FISH (IF-FISH) and detection of APBs. Cells
were permeabilized in Triton X-100 buffer (20 mM Tris-HCl, pH 8.0, 50
mMNaCl, 3 mMMgCl2, 0.5% Triton X-100, and 300 mM sucrose) for 5
min at room temperature and then fixed with 4% paraformaldehyde for
15 min at room temperature and permeabilized again in Triton X-100
buffer for 15min at room temperature. The cells were then blocked in 2%
bovine serum albumin (BSA) in phosphate-buffered saline (PBS) for 1 h
at room temperature and then incubated for 1 h at room temperaturewith
the 1st antibody diluted in 2% BSA. After a washing with 0.5% BSA in
PBS, the cells were incubated for 1 h at room temperature in the 2nd
antibody. When needed, FISH was next performed as follows. Briefly,
the cells were fixed again with 4% paraformaldehyde for 15 min at
room temperature, followed by washing in PBS and dehydration in a
series of ethanol (70%, 2 min; 85%, 2 min; and 100%, 2 min). A
telomeric Tel-Cy3 PNA probe from Panagene (Daejeon, South Korea)
was prepared at 200 nM (final concentration) in 70% formamide,
0.5% NEN blocking reagent (PerkinElmer), 10 mM Tris-HCl, pH 7.4.
The probe mixture was applied to the slides and denatured for 5 min at
75°C, followed by hybridization overnight at 37°C. The slides were
then washed with 70% formamide, 10 mMTris-HCl, pH 7.4, and 0.1%
BSA, followed by washes in PBS and incubation with DAPI (4=,6-
diamidino-2-phenylindole). Detection of ALT-associated promyelo-
ATRX and Telomeres
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cytic leukemia nuclear bodies (APBs) using anti-PML antibody
detection combined with telomere FISH (Tel-FISH) was conducted
according to previously described protocols (9, 19). Mouse monoclo-
nal anti-PML antibody, used for immunofluorescence analyses, was
from Santa Cruz Biotechnology (sc-966). The anti-SMC1 and anti-
ATRX antibodies used in immunofluorescence analyses were the same
as those used for ChIP (see above).
Telomere length measurement by telomere restriction fragment
(TRF) analysis. To analyze telomere length, genomic DNAs were pre-
pared, digested with RsaI and HinfI, and separated in a 0.9% agarose gel
(in Tris-borate-EDTA [TBE]) run in TBE buffer overnight and, after de-
naturation, transferred and hybridized with a (TTAGGG)3
32P-labeled
telomeric probe. The results were analyzed using a GE Storm phosphor-
imager and ImageGauge software.
RESULTS
ATRX localizes to subtelomeric regions of human glioma cells.
ATRX has recently been implicated in the telomerase-indepen-
dent mechanism of telomere maintenance, the so-called ALT
pathway. Thus, in several clinical studies, mutations in ATRX
were found to be tightly associated with the ALT pathway in var-
ious types of tumors (10, 11, 20–23). This correlation has also been
observed in cultured cells (24, 25). To understand how genetic
inactivation of ATRXmight interfere with telomeric pathways in
tumor cells and, in particular, favor the ALT pathway, we used
glioma cells in culture because gliomas have been reported to be
among the 5 to 15% of tumors that exhibited ALT-maintained
telomeres (9). Although several ALT-positive glioma cell lines
were recently isolated (26–28), most of the glioma cell lines iso-
lated to date utilize the telomerase pathway tomaintain functional
telomeres. With this in mind, the present objective was to analyze
in telomerase-positive glioma cells possible alterations in telo-
meric pathways following genetic inactivation of ATRX, as de-
scribed below. However, it was first necessary to try to determine
the intracellular localization of ATRX in these cells to see if it was
present near or at the telomeres, a localization that would be com-
patible with potential telomeric effects. Using a mouse monoclo-
nal antibody raised against amino acids 2193 to 2492 of human
ATRX,mapping near its C terminus, we analyzed the intracellular
distribution of ATRX by immunofluorescence. In two human gli-
oma cell lines, 8-MG-BA andHs-683, as well as in the nontumoral
HEK-293 human embryonic cell line, ATRX signals were present
throughout the nuclei in the form of dense, sharp spots but were
apparently absent from the cytoplasm, or at least present below
the levels detectable by the antibody (Fig. 1). FISH using a telo-
meric (CCCTAA) PNA probe was performed in the same experi-
ment in order to simultaneously localize the telomere termini at
chromosome ends. Strikingly, a large number of ATRX nuclear
spots localized very near a telomeric spot in both cell lines ana-
lyzed (Fig. 1). These experiments suggested that ATRX might be
present in the subtelomeric regions of the chromosomes in these
human glioma cell lines.
To confirm this finding, we set out to detect possible physical
interactions between ATRX and telomeric DNA. To do this, we
used ChIP, a technique that has been widely used in studies on
telomeric proteins. As shown in Fig. 2, in 8-MG-BA cells, ATRX
was found to be enriched in a subtelomeric region located1.1 kb
from the junction between telomeric and subtelomeric sequences
compared with a nontelomeric locus, GAPDH. To ascertain
whether ATRXpresence at subtelomeresmight bemeaningful, we
next compared the levels at this subtelomeric location to those at
another subtelomeric location, this time at a position close to the
TTAGGG telomere repeat. Interestingly, ATRX was more abun-
dant at the subtelomere at1.1 kb from the terminal repeat than
at the subtelomere-telomere junction; at the latter, ATRX enrich-
ment was just slightly above that at the GAPDH locus (Fig. 2B).
This findingwas confirmed using another pair of primers to assess
ATRX binding at positions close to the TTAGGG repeat other
than those illustrated in Fig. 2B (see Materials andMethods) (Fig.
2C). Note that, in Fig. 2B, the3-fold increase in ATRX detected
at the subtelomeric position nucleotide (nt)1122 compared to
the subtelomeric position nt 109 cannot be simply due to the
larger number of loci assessed for the subtelomere versus the sub-
telomere-telomere junction (seeMaterials andMethods). Indeed,
in these experiments, the ChIP data were normalized to the DNA
input in the PCRs.
Genetic inactivation ofATRX.As illustrated above, telomerase-
positive cultured cells, just like telomerase-positive tumors, exhibited
nuclear ATRX, as seen by immunofluorescence, whereas ALT-posi-
tive tumors and cultured cells exhibited total loss of nuclear ATRX
associatedwithmutations inATRX (10, 24). This is also illustrated in
Fig. 3A, in which we see that the 8-MG-BA and Hs-683 telomerase-
positive glioma cells used in the present study, as well HeLa cells,
contained nuclear ATRX, while the recently described ALT-positive
TG20 glioma stem cells (26) and thewidely usedALT-positiveU2OS
cells did not. We next used RNA interference (RNAi), both shRNA
and siRNA, to deplete 8-MG-BA and Hs-683 glioma cells of ATRX
RNA.Depending on the experiments and on the various clones gen-
erated following transfection of one or the other of two different
ATRX shRNAs, we observed an extinction ofATRXRNAof between
60 and 75% as measured by Q-RT-PCR (Fig. 3B). In experiments
using either one of two different siRNAs directed against ATRX se-
quences at targets identical to those defined for the two ATRX
shRNAs, extinction of ATRX RNA was even more efficient, close to
75 to 80% (Fig. 3D). In these experiments with shRNAs and siRNAs
against ATRX, we also evaluated the levels of ATRX protein after
RNA extinction using Western blotting. The ATRX gene yields two
major protein isoforms, a full-length 270- to 280-kDa protein and a
truncated form of 170 to 180 kDa that colocalizes at pericentromeric
heterochromatin (29). Note that the antibody used here could detect
only the larger of the two isoforms, and the 170-kDa band thus rep-
resents a nonspecific band that we used as a loading control (Fig. 3C,
E, and F). As shown in Fig. 3C and E, the 270- to 280-kDa ATRX
isoform was barely detectable following RNAi application, if at all in
some cases, in both cell lines compared with the negative controls
transfected with an shRNA targeting a scrambledATRX sequence or
a control siRNA.
We repeatedly observed that ATRX-inhibited cells clearly
started to lose adhesion to the cell culture substrate before reach-
ing confluence in the culture dish (data not shown). We hypoth-
esized that this might be related to apoptosis. Consequently, we
used detection of cell surface phosphatidylserine (PS) with an-
nexin V, a phospholipid-binding protein with high affinity for PS
labeled in green with fluorescein (annexin-V-FLUOS staining kit;
Roche) by flow cytometry as a marker for apoptosis. Cells were
simultaneously stained with a DNA red-staining dye, propidium
iodide, the exclusion of which, together with annexin V binding,
indicated apoptotic cells. Interestingly, using this assay, we were
able to determine that around 3% of atrx-minus cells were enter-
ing apoptosis, more than in cells transfected in parallel with the
Eid et al.
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DAPI Telo-FISH ATRX Merge
8MG-BA
HS-683 DAPI Telo-FISH ATRX Merge
DAPI Telo-FISH ATRX Merge
HEK-293
FIG 1 ATRX localizes close to telomere ends of 8-MG-BA (top two rows) and Hs-683 (middle row) human glioma cells and of nontumoral HEK-293 cells
(bottom row). Subcellular localization of ATRX (green) by immunofluorescence analysis using an anti-ATRXmonoclonal antibody and simultaneous telomere
FISH (red) indicated that ATRX frequently localized near—but not exactly at—the telomere ends.
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scrambled ATRX shRNA, in which only very few apoptotic events
were present (Fig. 3G).
Next, we used Tel-FISH, in combination with H2AX immu-
nostaining, to detect possible telomeric DNA damage after ATRX
had been genetically inactivated. The results of this analysis re-
vealed that the numbers of telomere dysfunction-induced foci
(TIF) per nucleus were similar in the glioma cells stably trans-
fected with ATRX shRNA compared with controls transfected
with scrambled ATRX shRNA (data not shown).
ATRX inactivation does not alter subtelomeric chromatin
accessibility to micrococcal nuclease. ATRX is a chromatin re-
modeler, and since we had shown (see above) that ATRX pref-
erentially localized to subtelomeric regions, we next wished to
test whether ATRX could impact higher-order chromatin
structure at subtelomeres. To address this question, we per-
formed MNase digestion assays on chromatin samples isolated
from an 8-MG-BA cell line in which ATRX had been stably
inactivated with ATRX shRNA and its control cell line express-
ing scrambled shRNA (Fig. 4). Time course experiments re-
vealed very similar profiles of MNase digestion in both cell
lines, suggesting that inactivation of ATRX does not impact
higher-order subtelomeric chromatin structure (Fig. 4A). Sim-
ilarly, when samples were digested for 5 min with various
amounts of MNase, there was no dramatic difference in subte-
lomeric chromatin digestion between cells in which ATRX had
been inactivated and control cells with wild-type ATRX (Fig.
4B). Based on these results, we conclude that the role of ATRX
at the subtelomeres is unlikely to be related to massive remod-
eling of subtelomeric chromatin.
Inactivation of ATRX results in decreased levels of TERRA
and of RNAP II at subtelomeres.Having shown that ATRX does
not massively impact higher-order subtelomeric chromatin, and
because of the previously established connection between ATRX
and telomere transcription (30–32), we next wished to test the
impact of ATRX depletion on TERRA levels in the glioma cell
lines. Telomeric DNA is indeed transcribed into noncoding RNA,
or TERRA (33). Inmammalian cells, TERRAmolecules have been
proposed to regulate telomere structuralmaintenance andhetero-
chromatin formation (31, 34). In mouse embryonic cells, upon
inactivation of ATRX, TERRA levels were found to either increase
(30) or remain unchanged (32), while in telomerase-positive hu-
man cells, inactivation of ATRX resulted in a diminution of
TERRA (35). To further document this issue, we set out to mea-
sure TERRA levels in cultured glioma cells stably transfected with
ATRX shRNA. Interestingly, we found that reducing ATRX ex-
pression led to a decrease in total TERRA levels in both theHs-683
and the 8-MG-BA telomerase-positive glioma cell lines (Fig. 5A).
Notably, this reductionwas not due to changes in telomere length,
as inactivation of ATRX did not lead to important changes in
telomere length (Fig. 5B).
We next investigated whether the diminution of TERRA levels
observed upon genetic inactivation of ATRX might result from
perturbations in the recruitment of RNAP II. Accordingly, ChIP
experiments revealed a drastic reduction in RNAP II recruitment
at the subtelomeres of 8-MG-BA and Hs-683 cells expressing
ATRX shRNA (Fig. 6A and B). Therefore, the present data suggest
that ATRX promotes RNAP II recruitment at human subtelom-
eres.
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FIG 2 Enrichment of ATRX in subtelomeric regions by ChIP. (A) Schematic representation of the positions (in nucleotides) of the PCR primers used for ChIP
analysis with respect to the telomeric terminal repeats, TTAGGG, together with the names of the telomeric genomic loci amplified by these primers (seeMaterials
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Downregulation of ATRX leads to decreased amounts of
SMC1/cohesin at subtelomeres.Our data indicate that ATRXde-
pletion impairs RNAP II recruitment at subtelomeres. Recently, it
was shown that in the postnatal mouse brain, ATRXwas recruited
concomitantly with cohesin at particular loci and that loss of
ATRX impaired cohesin recruitment at these loci (36). In addi-
tion, recent studies have shown that cohesin is an integral compo-
nent of human telomeric chromatin (16). We therefore set out to
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investigate whether inactivation of ATRX might affect the pres-
ence of cohesin at the telomeres by quantifying SMC1/cohesin
abundance at subtelomeric loci located directly upstream of telo-
meric repeats (Fig. 6A).WeusedChIP to analyze possible protein-
DNA interactions between SMC1/cohesin and telomeric DNA.
First, we could confirm the previous finding by Deng et al. (16) in
HCT116 cells that cohesin is indeed also enriched at the subtelom-
eres of the two glioma cell lines analyzed here (Fig. 6C andD).We
could further demonstrate that cells in which ATRX had been
partially inactivated either by shRNA or by siRNA exhibited a
dramatic decrease in the amount of SMC1/cohesin present at the
subtelomere (Fig. 6C and D). Altogether, therefore, our data sug-
gest that ATRX depletion impairs TERRA production through
downregulation of SMC1/cohesin loading at the subtelomere.
Genetic inactivation of ATRX is not sufficient to trigger the
ALT pathway of telomere maintenance. Previous experiments
showed that genetic inactivation of ATRX was not sufficient to
trigger ALT inHeLa cells (25).Wewished to confirm this result in
a glioma cell line, because this type of cell, in tumors, has a predis-
position to undergo ALT to maintain functional telomeres. We
therefore used the so-called C-circle assay to measure the number
of extrachromosomal telomeric DNA circles specific for the ALT
pathway of telomere maintenance (18). In this assay, partially sin-
gle-stranded telomeric (CCCTAA)n DNA circles (C-circles), which
presumably represent the result of the exchange between repeated
telomeric sequencesduring theALTprocesses, aredetected following
rolling-circle amplification by the Phi29 polymerase, which can am-
plify up to 70 kb of (TTAGGG)n DNA sequences in the absence of
dCTP. Production of these extrachromosomal telomeric DNAmol-
ecules that have been excised from the recombining telomeres, the
C-circles, accompanies all types of ALT cancer cells studied to date
(18). The experiments performed here indicated that genetic inacti-
vation of ATRX was not sufficient to trigger the appearance of the
C-circles in these telomerase-positive glioma cells (Fig. 7A). This was
assessed at early passages, 3 and 6, following transfection with
shRNAs/siRNAs (data not shown), as well as later, after 30 passages
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(Fig. 7A). We also assessed the presence of the ALT-associated so-
called APBs (9, 19) in 8-MG-BA cells depleted of ATRX or not by
RNAi. Consistent with the finding described above that the ALT-
associatedC-circleswerenot inducedbyATRX inactivation,noAPBs
couldbedetected following efficientdepletionofATRX(Fig. 7B).On
the other hand, as expected and as shown previously (26), cells from
the TG20 glioma stem cell line exhibited clearly visible APBs in the
form of PML bodies perfectly colocalizing with telomere termini la-
beled by FISH (Fig. 7B). Conversely, an ALT-positive U2OS cell line
overexpressingATRX in a stable manner did not result, after up to 2
months of selection, in the inhibition of the number of ALT-associ-
ated C-circles in these cells compared with cells expressing an empty
vector (data not shown). It should be noted, however, that ATRX
isoform 1 expressed from the IF-GFP-ATRX plasmid is actually not
completely wild type because it lacks exon 6. Although perhaps un-
likely, the possibility that themissing sequences have an effect on the
function of the protein and the inability of the ATRX construct to
reverse the ALT pathway in ALT-positive cells cannot be completely
ruled out.
DISCUSSION
In the present paper, we report that genetic inactivation of the
chromatin-remodeling protein ATRX in human telomerase-pos-
itive cancer cells impinges both on the presence of cohesin in
subtelomeric regions of the chromosomes and on the level of tran-
scription of telomeric DNA into TERRA. The latter possibly re-
sulted from impaired transcription, as RNAP II levels were also
severely depressed following ATRX inactivation. Previous find-
ings, mainly from clinical studies, have pointed to the simultane-
ous occurrence of a mutation in ATRX and of the telomerase-
independent ALT pathway in several types of tumors (10, 11, 20–
23). This list is not exhaustive, as other, more recent studies have
confirmed these early findings. However, these studies failed to
identify possible targets of ATRX. The experiments performed
here indicated that genetic inactivation ofATRXwas not sufficient
to trigger the appearance of the ALT-associated C-circles in te-
lomerase-positive glioma cells, thus confirming a recent study us-
ing the same approach inHeLa cells (25). The present data provide
important clues to start to understand the relationship between
genetic inactivation of ATRX and the ALT pathway.
In the present study, we found by both IF-FISH and ChIP that
ATRX localized at the subtelomeres but not at the very ends of the
telomeres of glioma cells. ATRX enrichment has been previously
reported at subtelomeres and telomeres of human primary cells
and mouse embryonic stem cells (37, 38). More recently, Atrx-
null mouse embryonic brain cells were shown to exhibit telomeric
damage that could be worsened by treatment with the G-quadru-
plex ligand telomestatin, suggesting a role for ATRX in the repli-
cation of telomeric G4-DNA structures (39). Inmouse embryonic
stem cells, ATRX and H3.3 colocalized within PML bodies con-
taining telomeric DNA (40). Interestingly, such PML bodies likely
correspond to the APBs found inALT-positive cancer cells (9, 19).
These mouse embryonic stem cells have not been reported to ex-
perience any ALT-mediated pathway of telomere maintenance,
and obviously, the role of ATRX in these cells is different from that
in cancer cells, as the latter have lost ATRX function. It is tempting
to speculate that, in both humans and mice, ATRX’s prominent
role is in the maintenance of telomeric chromatin and that, for
some as yet unknown reasons, loss of ATRX function in human
tumors leads to the triggering of the ALT pathway, while inmouse
embryonic stem cells, ATRX helps in telomeric DNA replication.
It is also tempting to speculate that, in telomerase-positive human
cancer cells, ATRX also helps in telomeric DNA replication and
that upon fortuitous loss of ATRX function, perturbation in telo-
mere replication leads to recombination-based ALT.
Reducing ATRX expression led here to a decrease in total
TERRA levels in both the Hs-683 and the 8-MG-BA telomerase-
positive glioma cell lines. This was in contrast to recent findings in
mouse embryonic stem cells, in which inactivation ofATRX led to
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upregulation of TERRA (30), and inmouse embryonic fibroblasts,
in which TERRA levels remained unchanged upon ATRX inacti-
vation (32), but was in agreement with another recent study in
which loss ofATRX function led to a reduction in TERRA levels in
a human telomerase-positive cell line (35). Overall, this suggests
that regulation of telomere transcription is different in mice and
humans. In addition, based on previous findings (16), the present
data suggest that the diminution in cohesin levels at subtelomeres
in cells with ATRX inactivated might be responsible for the dimi-
nution of TERRA levels observed here. Indeed, in that study, in-
activation of RAD21/cohesin resulted in severe impairment of
TERRA transcription (16). Moreover, the present data tend to
suggest that ATRX may, possibly through an effect on cohesin
recruitment and/or maintenance at telomeric chromatin, facili-
tate TERRA transcription by increasing RNAP II binding at the
telomeres. Alternatively, the present, as well as the recent (35),
findings that ATRX inactivation diminished TERRA levels might
be explained by the occurrence of a concomitant loss of control of
histone/DNA methylation at the subtelomeres. Indeed, in mouse
embryonic stem cells, disruption of ATRX/H3.3 binding led to a
loss of control of the telomeric histone methylation pattern (39),
and in human cells, TERRA abundance is negatively regulated by
methylation of TERRApromoter CpG islands (41). Of note, it was
recently reported that genetic inactivation of ATRX led to persis-
tence of both TERRA and RPA foci at telomeres of HeLa cells in
G2/M, suggesting a role for ATRX in cell cycle-dependent regula-
tion of TERRA abundance at telomeres (42). It was proposed that
the hnRPA1-mediated RPA-displacing activity normally inhib-
ited byTERRAonly during early S phase (43)was now abnormally
inhibited atG2/Mdue to genetic inactivation ofATRX and that the
resulting elevation of telomeric RPA levels led to recruitment of
ATR and potentially to the recombination events characteristic of
ALT (42).
How the global reduction of TERRA levels upon ATRX knock-
down and the impact of ATRX on TERRA cell cycle regulation are
connected is still unknown. Recent data have shown that the
NuRD deacetylase complex was recruited at ALT telomeres
through orphan receptor binding and induced hypoacetylation of
telomeric chromatin, potentially causing a diminution in the
markers associated with open -state chromatin (44). The telo-
meres of ALT cells are decompacted compared to those of telom-
erase-positive cells (35), and Conomos et al. (44) have proposed
that NuRD recruitment might partly compensate for this decom-
paction of telomeric chromatin. One hypothesis is that this dra-
matic decondensation of telomeric chromatin in ALT cells needs
to be partially compensated for in order to avoid excessive activa-
tion of the DNA damage response at telomeres and chromosomal
instability. We now propose that ATRX loss of function might act
in synergy with recruitment of NuRD as part of a putative feed-
back mechanism aimed at partly reconstituting functional telo-
meric heterochromatin compatible with survival (a model is
shown in Fig. 8). In addition, as discussed above, inactivation of
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ATRXmight play an important role in the TERRA-induced RPA-
to-POT1 switch that potentially results in inappropriate presence
of ATR at the telomeres and triggering of ALT (42, 43). Further
experimentationwill be required to test thesemodels. In addition,
how telomeric chromatin relaxation, TERRA upregulation, and
ATRX loss contribute to the ALTmechanism remains to be estab-
lished.
It is now clear that repression of ATRX cannot, on its own,
activate ALT, although, on the other hand, several pieces of data
suggest that mutation of ATRX is necessary for ALT induction.
Alternatively, ATRX could act as a suppressor of ALT in telomer-
ase-positive cells, which could also explain the association be-
tween an ATRXmutation and the ALT status. In this hypothesis,
reestablishing ATRX expression in ALT cells should inhibit the
ALT mechanism. However, under our experimental conditions,
at least, overexpression of ATRX did not seem to alter the level of
ALT-specific C-circles. Therefore, if ATRX is an inhibitor of ALT,
other conditions, such as cooverexpression of one or several other
proteins, must be fulfilled in order to observe the result of this
action.
In the budding yeast Saccharomyces cerevisiae, type II telomeric
recombination generates highly heterogeneous terminal restric-
tion fragments, which can attain 20 kb or more after telomere
elongation, resembling those present in human ALT cells and
probably mechanistically similar (45). On the other hand, in te-
lomerase-negative yeast cells, type I recombination amplifies the
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subtelomeric sequences. It is notable that, in human cells, the
absence of ATRX, which we find to bemainly localized at the sub-
telomeres, is associated with ALT recombination (at least in all
clinical samples analyzed), an event that presumably takes place
only at the level of telomeric sequences, mainly involving TT
AGGG repeats (46). Strikingly, ATRX is a homolog of S. cerevisiae
Rad54 (47; http://www.ensembl.org) and Rad54 is essential for
operating type I recombination at S. cerevisiae subtelomeres (48,
49). In yeast, Rad54 is required for subtelomeric recombination
but not for telomeric recombination, while humanATRX appears
to have to be inactivated before telomeric recombination can take
place. Telomerase-negative S. cerevisiae cells lacking the RAD54
gene survive by usingALT-like type II recombination (48, 49). It is
tempting to speculate that in humans, telomerase-negative tumor
cells with a fortuitous mutation in ATRX cannot perform subte-
lomeric recombination and that they amplify only their telomeric
sequences, just like S. cerevisiae rad54 mutants that can perform
only ALT-like type II recombination. In this hypothesis, telomer-
ase-negative tumors with wild-type ATRX amplifying their subte-
lomeric sequences may potentially exist. Notably, there are some
types of human cancer in which a substantial subset of the tumors
do not have evidence either of ALT or of telomerase activity (50,
51). Perhaps some of these tumors survive owing to subtelomeric
recombination. It should also be noted that the presence of TGA
GGG, TCAGGG, and TTGGGG variant repeats, found in large
quantities in ALT cells, implies subtelomeric recombination dur-
ing the process of acquisition of ALT (46).We speculate that some
subtelomeric factors, such as cohesin (the subtelomeric localiza-
tion of which was found here to depend on ATRX), might be
involved in subtelomeric recombination, for instance, owing to its
role in maintaining sister chromatids in close proximity, thereby
favoring recombination.
In summary, our findings reveal cohesin, as part of telomeric
chromatin, to be a potentially important actor in the mechanisms
of the telomerase-independent ALT pathways that accompany all
known cases of tumors with a mutation in the chromatin remod-
eler ATRX. Togetherwith those of Episkopou et al. and Flynn et al.
(35, 42), our data also suggest that the potential control of TERRA
by ATRX represents a key event in the functioning of the ALT
pathway (Fig. 8). Our present finding that ATRX controls telo-
meric cohesin, together with the recent finding by Deng et al. (16)
that telomeric cohesin regulates TERRA transcription, dictates a
necessary orientation of future research toward understanding
these relationships. It might also be pertinent to try to find func-
tional interactions between ASF1 and ATRX (and to know
whether cohesinmight play a role in such interactions), as ASF1, a
major regulator of chromatin organization, was recently found to
negatively control the ALT pathway (52). Finally, recent data
showing, in mice, that ATRX regulates the expression of genes in
intragenic G-rich regions and allows optimal RNAP II function at
these sites (32) leave open the possibility that loss of ATRX func-
tion in ALT tumors correlates with the acquisition of a particular
transcriptional program uniquely compatible with the survival of
cells that have undergone telomeric recombination.
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